- Home
- MRNS vs BHAC Comparison
MRNS vs BHAC Comparison
Compare MRNS & BHAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNS
- BHAC
- Stock Information
- Founded
- MRNS 2003
- BHAC 2021
- Country
- MRNS United States
- BHAC United States
- Employees
- MRNS N/A
- BHAC N/A
- Industry
- MRNS Biotechnology: Pharmaceutical Preparations
- BHAC Blank Checks
- Sector
- MRNS Health Care
- BHAC Finance
- Exchange
- MRNS Nasdaq
- BHAC Nasdaq
- Market Cap
- MRNS 76.0M
- BHAC 74.1M
- IPO Year
- MRNS 2014
- BHAC 2021
- Fundamental
- Price
- MRNS $1.43
- BHAC $10.60
- Analyst Decision
- MRNS Buy
- BHAC
- Analyst Count
- MRNS 7
- BHAC 0
- Target Price
- MRNS $8.00
- BHAC N/A
- AVG Volume (30 Days)
- MRNS 390.0K
- BHAC 5.3K
- Earning Date
- MRNS 11-05-2024
- BHAC 01-01-0001
- Dividend Yield
- MRNS N/A
- BHAC N/A
- EPS Growth
- MRNS N/A
- BHAC N/A
- EPS
- MRNS N/A
- BHAC 0.16
- Revenue
- MRNS $30,263,000.00
- BHAC N/A
- Revenue This Year
- MRNS $20.42
- BHAC N/A
- Revenue Next Year
- MRNS $57.03
- BHAC N/A
- P/E Ratio
- MRNS N/A
- BHAC $64.26
- Revenue Growth
- MRNS 16.56
- BHAC N/A
- 52 Week Low
- MRNS $1.05
- BHAC $10.11
- 52 Week High
- MRNS $11.26
- BHAC $12.80
- Technical
- Relative Strength Index (RSI)
- MRNS 55.91
- BHAC 36.86
- Support Level
- MRNS $1.38
- BHAC $10.11
- Resistance Level
- MRNS $1.43
- BHAC $10.73
- Average True Range (ATR)
- MRNS 0.07
- BHAC 0.06
- MACD
- MRNS 0.00
- BHAC -0.01
- Stochastic Oscillator
- MRNS 47.62
- BHAC 71.54
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
About BHAC Focus Impact BH3 Acquisition Company
Focus Impact BH3 Acquisition Co is a blank check company.